PDSB Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
6.5M
-0.4%
6.5M
-2.3%
6.7M
-18.0%
8.1M
+6.8%
7.6M
R&D
3.3M
-5.5%
3.5M
-21.5%
4.4M
-3.7%
4.6M
+8.6%
4.2M
SG&A
3.2M
+5.5%
3.1M
+35.0%
2.3M
-36.3%
3.6M
+4.5%
3.4M
Operating Income
-6496734
+0.4%
-6521087
+2.3%
-6674708
+18.0%
-8140142
-6.8%
-7623351
EBITDA
-6488347
+0.4%
-6515628
+2.3%
-6669249
+18.0%
-8134683
-6.8%
-7617892
Net Income
-9750575
-32.7%
-7349056
+2.8%
-7562919
+16.1%
-9009411
+4.5%
-9434208
EPS (Basic)
$-0.18
-38.5%
$-0.13
+7.1%
$-0.14
+26.3%
$-0.19
+9.5%
$-0.21
EPS (Diluted)
$-0.18
-38.5%
$-0.13
+7.1%
$-0.14
+26.3%
$-0.19
+9.5%
$-0.21
Shares (Diluted)
55.7M
+0.3%
55.5M
+6.2%
52.2M
+11.5%
46.9M
+2.1%
45.9M
PDS Biotechnology (PDSB) โ€” Financials